Clinical stage I
Asymptomatic.
Generalized lymphadenopathy.
Performance scale 1: asymptomatic, normal activity.

Clinical stage II
Weight loss, < 10% of body weight.
Minor mucocutaneous manifestations (seborrheic dermatitis, prurigo, fungal nail infections, recurrent oral ulcerations, angular cheilitis).
Herpes zoster within the last five years.
Recurrent upper respiratory tract infections (i.e., bacterial sinusitis).
And/or performance scale 2: symptomatic, normal activity.

Clinical Stage III
Weight loss, > 10% of body weight.
Unexplained chronic diarrhea > 1 month.
Unexplained prolonged fever (intermittent or constant), > 1 month.
Oral candidiasis (thrush).
Oral hairy leucoplakia.
Pulmonary tuberculosis.
Severe bacterial infections (i.e., pneumonia, pyomyositis).
And/or performance scale 3: bedridden < 50% of the day during last month.

Clinical stage IV
HIV wasting syndrome.
Pneumocystis carinii pneumonia.
Toxoplasmosis of the brain.
Cryptosporidiosis with diarrhea > 1 month.
Cryptococcosis, extrapulmonary.
Cytomegalovirus disease of an organ other than liver, spleen, or lymph node.
Herpes simplex virus infection, mucocutaneous (>1 month) or visceral.
Progressive multifocal leucoencephalopathy.
Any disseminated endemic mycosis.
Candidiasis of esophagus, trachea, bronchi.
Atypical mycobacteriosis, disseminated or lungs.
Non-typhoid Salmonella septicemia.
Extrapulmonary tuberculosis.
Lymphoma.
Kaposi's sarcoma.
HIV encephalopathy.
And/or performance scale 4: bedridden > 50% of the day during last month.

WHO. Scaling up antiretroviral therapy in resource-limited settings. Treatment guidelines for a public health approach. Guidelines for assessment. Annex E, p. 61. Geneva: WHO, 2003. Internet. Accessed on January 25, 2016.